LENVIMA RAI-R DTC Video Library
Understanding the SELECT trial in patients with RAI-R DTC
Dr Mark Lupo reviews the efficacy and safety data from the SELECT trial. This presentation covers the study's design, endpoints, results, and important safety information.
RAI-R DTC real-world data
Dr Lupo gives an overview of efficacy and safety data, including clinical outcomes and physician-reported DCR, BOR, PFS, and OS.
Understanding the SELECT trial in patients with RAI-R DTC
RAI-R DTC real-world data
SELECT=Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid; RAI-R=radioactive iodine-refractory; DTC=differentiated thyroid cancer; DCR=disease control rate; BOR=best overall response; PFS=progression-free survival; ORR=objective response rate; OS=overall survival.
Featured HCP
Mark Lupo, MD, FACE, ECNU
Endocrinologist and Medical Director
The Thyroid & Endocrine Center of Florida
Sarasota, Florida
Sponsored by Eisai Inc., Dr Mark Lupo was paid for his participation in this video.
Dr Mark Lupo is the founder and Medical Director of the Thyroid & Endocrine Center of Florida. He is board-certified in Endocrinology and Internal Medicine. Dr Lupo attended Duke University and earned his medical degree and internal medicine training from the University of Florida. He completed endocrinology training through a combined program at the University of California, San Diego and Scripps Clinic. He is also a Clinical Assistant Professor, Florida State University College of Medicine, a member of the Board of Directors of the American Association of Clinical Endocrinologists (AACE), and the current Secretary of the Academy of Clinical Thyroidologists. Dr Lupo lectures nationally and internationally on the topic of thyroid nodules and teaches neck ultrasound in the evaluation of nodules and cancer to other endocrinologists and surgeons.